Anzeige
Mehr »
Sonntag, 15.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CSAN | ISIN: SE0015382080 | Ticker-Symbol: 8E8
München
13.02.26 | 08:05
0,466 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ELICERA THERAPEUTICS AB Chart 1 Jahr
5-Tage-Chart
ELICERA THERAPEUTICS AB 5-Tage-Chart
GlobeNewswire (Europe)
106 Leser
Artikel bewerten:
(0)

Elicera Therapeutics AB: Elicera Therapeutics announces final data from its Phase I/IIa trial demonstrating a favorable safety profile and promising efficacy signals of oncolytic virus ELC-100 in neuroendocrine tumors

Gothenburg, January 9, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology platform iTANK, today announces final data from its Phase I/IIa clinical trial evaluating the oncolytic virus ELC-100 in patients with advanced, end-stage neuroendocrine tumors who had exhausted all currently available therapeutic options and having progressing diseases. The study demonstrates that ELC-100, was generally well-tolerated with no dose-limiting toxicities observed. Importantly, the trial also revealed promising efficacy signals, including partial tumor responses in two out of eight patients evaluable for efficacy, providing early evidence of anti-tumor activity in this highly treatment-resistant population.

Safety results
ELC-100 (formerly referred to as AdVince) was generally well-tolerated, with no dose-limiting toxicities (DLTs) observed in any of the 12 treated patients. The safety profile was consistent with the expected mechanism of action of an oncolytic virus, characterized by a manageable inflammatory response. Maximum tolerated dose was established at 1 x 1012 virus particles as the highest tested dose.

Encouraging Efficacy signals
Notably, in this highly challenging patient population, consisting of individuals with advanced, end-stage neuroendocrine tumors who had exhausted all currently available treatment options, promising preliminary signals of clinical efficacy were observed. Specifically, partial responses in 2 of 8 efficacy-evaluable patients. Twelve weeks after the 4thtreatment cycle, 75% of efficacy-evaluable patients (n=8) remained progression free.

Jamal El-Mosleh, CEO of Elicera Therapeutics, commented:

"These are encouraging results from our Phase I/IIa safety trial with ELC-100. In this study of 12 patients with advanced metastatic neuroendocrine tumors, we observed a favorable safety profile with no dose-limiting toxicities and manageable adverse events consistent with the mechanism of an oncolytic virus. Importantly, we saw partial responses in two out of eight patients evaluable for efficacy, which represents meaningful early evidence of anti-tumor activity in a disease setting where new treatment options are needed. We are deeply grateful to the Victory NET Foundation for their generous financial support, which has made it possible to complete this important trial and advance the research and development of innovative therapies for this difficult-to-treat patient population. Given these positive signals, we will now carefully evaluate our strategic options for the continued development of the ELC-100 program."

About the Phase I/IIa study

The clinical Phase I/IIa-study "Study of Recombinant Adenovirus AdVince in Patients with Neuroendocrine Neoplasms; Safety and Efficacy", enrolled 12 patients in total, in four escalating dose groups. Patients in each dose group received up to eight repeating doses of AdVince via hepatic artery infusion or intra-tumoral injection, with the primary objective of evaluating safety and determining maximum tolerated dose.

Secondary objectives include to evaluate the anti-tumoral efficacy of AdVince infusions on metastatic neuroendocrine tumors and to determine the number of patients with progression-free-survival (PFS) twelve weeks after the 4thtreatment cycle.

Efficacy population (n=8): All patients who had received at least one treatment period (four treatment cycles) of investigational product (AdVince, ELC-100) and had both baseline and evaluation of CT data (at the 1-month follow-up visit).

For further information, please contact:

Jamal El-Mosleh, CEO, Elicera Therapeutics AB (publ)

Phone: +46 (0) 703 31 90 51
jamal.elmosleh@elicera.com

Certified Advisor

DNB Carnegie Investment Bank (publ)

About Elicera Therapeutics AB
Elicera Therapeutics AB (publ) has developed the patented gene technology platform iTANK that enables the arming of new and existing CAR T-cell therapies targeting aggressive and relapsing cancer forms. Elicera Therapeutics thereby addresses a well-defined and vast market. The company's CAR T-cell therapies have shown a potent effect toward solid tumors which are recognized as particularly difficult to treat and constitute the majority of cancer cases. The company addresses a global multibillion market in cell therapy through its offering of non-exclusive licensing of the iTANK-platform to companies in the pharmaceutical industry. Elicera Therapeutics has four internal development projects in immune therapy that separately have the potential to generate substantial value through exclusive out-licensing agreements. The company's share is traded on Nasdaq First North Growth Market. For additional information, visit www.elicera.com.


© 2026 GlobeNewswire (Europe)
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.